Literature DB >> 32372477

Highly upregulated in liver cancer (HULC): An update on its role in carcinogenesis.

Soudeh Ghafouri-Fard1, Mohammadhosein Esmaeili2, Mohammad Taheri3, Majid Samsami4.   

Abstract

Highly upregulated in liver cancer (HULC) was initially recognized during the screening of a hepatocellular carcinoma (HCC)-specific gene library. Further studies demonstrated its aberrant upregulation in several other tumor types. The oncogenic roles of this long noncoding RNA (lncRNA) have been verified through expression studies as well as functional studies. Moreover, the results of knockdown experiments have indicated diminished carcinogenic effects of cancer cell line in nude mice following HULC silencing. More recent studies have shown that expression levels of this lncRNA might be used as diagnostic biomarkers in cancer patients. Moreover, mechanistical studies have revealed associations between HULC and two HCC-related viruses namely hepatitis B and C viruses. Taken together, HULC can be regarded as a therapeutic target not only for HCC but also for a variety of human malignancies. In the current review, we summarized the recent literature about the role of HULC in the carcinogenesis and its potential application in cancer diagnosis and prognosis.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  HULC; biomarker; cancer

Mesh:

Substances:

Year:  2020        PMID: 32372477     DOI: 10.1002/jcp.29765

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  9 in total

1.  Long Non-Coding RNA TRIM52-AS1 Promotes Growth and Metastasis via miR-218-5p/ROBO1 in Hepatocellular Carcinoma.

Authors:  Yuanjun Liu; Yakun Wu; Shuang Liu; Yi Dai
Journal:  Cancer Manag Res       Date:  2021-01-22       Impact factor: 3.989

2.  Identifying modules of cooperating cancer drivers.

Authors:  Michael I Klein; Vincent L Cannataro; Jeffrey P Townsend; Scott Newman; David F Stern; Hongyu Zhao
Journal:  Mol Syst Biol       Date:  2021-03       Impact factor: 11.429

Review 3.  Circulating Long and Circular Noncoding RNA as Non-Invasive Diagnostic Tools of Hepatocellular Carcinoma.

Authors:  Caecilia H C Sukowati; Loraine Kay D Cabral; Claudio Tiribelli; Devis Pascut
Journal:  Biomedicines       Date:  2021-01-19

4.  LncRNA MAGI2-AS3 acts as a tumor suppressor that attenuates non-small cell lung cancer progression by targeting the miR-629-5p/TXNIP axis.

Authors:  Jun Gong; Lei Ma; Chunlei Peng; Jianhua Liu
Journal:  Ann Transl Med       Date:  2021-12

5.  Whole-genome-scale identification of novel non-protein-coding RNAs controlling cell proliferation and survival through a functional forward genetics strategy.

Authors:  D P Tonge; D Darling; F Farzaneh; G T Williams
Journal:  Sci Rep       Date:  2022-01-07       Impact factor: 4.379

Review 6.  The Roles and Mechanisms of lncRNAs in Liver Fibrosis.

Authors:  Zhifa Wang; Xiaoke Yang; Siyu Gui; Fan Yang; Zhuo Cao; Rong Cheng; Xiaowei Xia; Chuanying Li
Journal:  Front Pharmacol       Date:  2021-11-24       Impact factor: 5.810

Review 7.  Emerging role of lncRNAs in drug resistance mechanisms in head and neck squamous cell carcinoma.

Authors:  José A Peña-Flores; Mercedes Bermúdez; Rosalío Ramos-Payán; Carlos E Villegas-Mercado; Uriel Soto-Barreras; Daniela Muela-Campos; Alexis Álvarez-Ramírez; Brenda Pérez-Aguirre; Ana D Larrinua-Pacheco; César López-Camarillo; Jorge A López-Gutiérrez; Julio Garnica-Palazuelos; Marvin E Estrada-Macías; Juan L Cota-Quintero; Andrés A Barraza-Gómez
Journal:  Front Oncol       Date:  2022-08-01       Impact factor: 5.738

8.  Development of a Predictive Immune-Related Gene Signature Associated With Hepatocellular Carcinoma Patient Prognosis.

Authors:  Jiasheng Lei; Dengyong Zhang; Chao Yao; Sheng Ding; Zheng Lu
Journal:  Cancer Control       Date:  2020 Jan-Dec       Impact factor: 3.302

Review 9.  The Nucleus/Mitochondria-Shuttling LncRNAs Function as New Epigenetic Regulators of Mitophagy in Cancer.

Authors:  Yan Li; Wei Li; Andrew R Hoffman; Jiuwei Cui; Ji-Fan Hu
Journal:  Front Cell Dev Biol       Date:  2021-09-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.